Options Traders Expect AstraZeneca Shares To Fall After Earnings Report, As Stock Is Up 5% In 2022 - AstraZeneca (NASDAQ:AZN)Benzinga • 11/09/22
AstraZeneca shares will get lift from heartburn litigation closure, says CitiProactive Investors • 11/01/22
Invitae Announces Partnership for Real-World Data Sharing to Inform Rare Cancer ResearchPRNewsWire • 10/27/22
Camizestrant Significantly Improved Progression-free Survival Vs. FASLODEX® (fulvestrant) in SERENA-2 Phase II Trial in Advanced ER-positive Breast CancerBusiness Wire • 10/26/22
Capivasertib plus FASLODEX® (fulvestrant) significantly improved progression-free survival vs. FASLODEX in CAPItello-291 Phase III trial in advanced HR-positive breast cancerBusiness Wire • 10/26/22
AstraZeneca says advanced trial of breast-cancer drug Capivasertib meets primary endpointsMarket Watch • 10/26/22
AstraZeneca trial of Fasrena fails to meet one of two dual-primary endpointsProactive Investors • 10/25/22
AstraZeneca says Imjudo-Imfinzi combination approved in advanced liver cancer in USProactive Investors • 10/24/22